Elevian Raises $40 Million Series A To Advance Treatments For Stroke Recovery And Age-Related Diseases
Sep 16, 2021•almost 4 years ago
Amount Raised
$40 Million
Round Type
series a
Description
Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced that it raised $40 million in an oversubscribed Series A round led by Prime Movers Lab. The funding will enable Elevian to submit an investigational new drug application, scale manufacturing and complete Phase 1 clinical trials for its lead indication of stroke recovery.
FundzWatch™ Score
71
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech